Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "Citi"

770 News Found

Gland Pharma to buy French pharma company Cenexi
News | November 30, 2022

Gland Pharma to buy French pharma company Cenexi

Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group


Reforms in Ayush to boost growth: Sarbananda Sonowal
News | November 24, 2022

Reforms in Ayush to boost growth: Sarbananda Sonowal

Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister


Centre deploys three teams to manage high measles cases among children
News | November 24, 2022

Centre deploys three teams to manage high measles cases among children

The teams will assist the state health authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures


SMS Pharma revenue down 9%
News | November 15, 2022

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market


Voltas forays into the bio medical refrigeration and cold chain
Supply Chain | November 15, 2022

Voltas forays into the bio medical refrigeration and cold chain

Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market


Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
News | November 14, 2022

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers


Ayu Health receives US $27 million additional funding
News | November 11, 2022

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model


Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
News | November 07, 2022

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY


Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.